Brief: Cyxone Will Leverage Ind And Use FDA Pre-Review For Covid-19 Phase 2 Trial

Cyxone AB

24/09/2021 10:21

Sept 24 (Reuters) - Cyxone AB  CYXO.ST :
    * CYXONE WILL LEVERAGE IND AND USE FDA PRE-REVIEW FOR COVID-19 PHASE 2 TRIAL
    * CYXONE WILL LEVERAGE IND AND USE FDA PRE-REVIEW FOR COVID-19 PHASE 2 TRIAL
    * IS EXPECTING TO COMMUNICATE TOP-LINE RESULTS FROM A RECENTLY CONCLUDED PHASE 2 TRIAL OF
ITS DRUG
CANDIDATE RABEXIMOD IN COVID-19 PATIENTS DURING Q4
    * RESULTS WERE PREVIOUSLY SLATED FOR Q3

Source text for Eikon:  ID:nWkr2K1pxb 
Further company coverage:  CYXO.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))